Metabolic Effectiveness of Extracorporeal Shockwave on Abdominal Adiposity
Enrolling by invitation · Not applicable
Conditions studied: Abdominal Obesity, Abdominal Obesity-Metabolic Syndrome, Abdominal Obesity in Young and Middle Aged Adults
In brief
Egyptian Ministry of Health and Population's Preventive Sector, have named obesity as one of the top contributors to the national mortality and morbidity. Abdominal obesity is a strong predictor of metabolic disorders and premature mortality. Visceral fat is metabolically active and sensitive for lipolysis, unless it is more insulin resistant. It is well-known that overweight and/ or obesity is associated with overactivated proinflammatory cytokines those overactivated inflammatory process thus led to organs dysfunction across persistent low-grade inflammations . Recently, extracorporeal shock wave represents a promising, non-invasive management strategy supporting the treatment of a variety of conditions related to plastic surgery. As well, it displayed a good safety profile with no serious adverse events . The need of this study develops from the lack in the quantitative knowledge and information regarding overall metabolic effectiveness of the Extracorporeal Shockwave on abdominal adiposity.
Key facts
- Study ID
- NCT07686601
- Run by
- Cairo University
- People needed
- 90
- Starts
- 2026-06-01
- Expected to finish
- 2027-05-30
- Last updated by the study team
- 2026-07-07
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- This study will be delimited by:
- Age > 18years old.
- All of them suffered from abdominal obesity.
- All have waist/ hip ratio of > 0.85 and their waist circumference > 90 cm.
You may not qualify if…
- Patients who had the following features will be excluded from the study:
- Patients with diabetes mellitus, heart and/ or vascular, renal, hepatic, pulmonary, neurological, psychological, and or mental disorders are excluded.
- Patients who had autoimmune diseases were excluded.
- Patients with hypertension, metal or electronic implants were excluded.
- Patients, who have intra-abdominal mesh and/ or unrepaired abdominal hernia were excluded.
- Patients who have cancer were excluded.
- Patients who have scars, open lesions and wounds at treatment area were excluded.
- Patients who have any intervention to lose weight or body contouring within the last 6 months (diet, exercise or body contouring devices) were excluded.
- Patients who received pharmacological drugs for controlling obesity were excluded.
Where it is running
- Shebin ElKom Teaching Hospital — Shibīn al Kawm, Menofyia, Egypt
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.